Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Payers' Guide
Select Drug Profiles
,
Payers' Guide
Tremfya (Guselkumab), First-in-Class IL-23 Blocker, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Xadago (Safinamide), an Oral MAO-B Inhibitor, FDA Approved as Adjunctive Treatment for Patients with Parkinson’s Disease
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Xeljanz/Xeljanz XR (Tofacitinib/Tofacitinib XR), an Oral JAK Inhibitor, Now Approved for Adults with Active Psoriatic Arthritis
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Xermelo (Telotristat Ethyl), First-in-Class Tryptophan Hydroxylase Inhibitor, Approved for Carcinoid Syndrome Diarrhea
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Yescarta (Axicabtagene Ciloleucel) Second CAR T-Cell Therapy Approved for Patients with Certain Types of Large B-Cell Lymphoma
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Darzalex (Daratumumab) Approved as Part of a 3-Drug Regimen for Patients with Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Defitelio (Defibrotide Sodium): First Drug Approved for Patients with Hepatic Veno-Occlusive Disease
Laura Morgan
Read More
2
3
4
5
6
7
8
Page 5 of 19
Results 41 - 50 of 185